EUCTR2014-004176-35-Outside-EU/EEA进行中（未招募）不适用
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post Surgical Dental Pain: Study I
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer
- 入组人数
- 316
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females 16 years to 40 years of age (inclusive).
- •2. Outpatients who have moderate to severe post-operative pain (confirmed by a Visual Analog Scale Pain Severity Rating Scale (VAS-PSR) score of at least 50 mm on a 100-mm VAS-PSR) following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction.
- •3. Use of only the following pre-operative medication(s)/anesthetic(s): topical benzocaine, a short-acting parenteral (local) anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide.
- •4. Examined by the attending dentist or physician and medically cleared to participate in the study.
- •5. In general good health and have no contraindications to the study or rescue medication.
- •6. Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form.
- •7. Subjects (or the parent or legal guardian of subjects under the age of 18 years) are required to read, comprehend, and sign the informed consent. Subjects requiring a parent or legal guardian to sign the informed consent form will also be required to sign an assent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 111
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 205
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Presence or history of any significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorder determined by the Principal Investigator to place the subject at increased risk.
- •2.Use of a prescription or over-the-counter (OTC) drug with which administration of ibuprofen or any other non-steroidal anti-inflammatory drug (NSAID), acetaminophen (APAP), or hydrocodone is contraindicated (including: opioids, antipsychotics, antianxiety agents, or other central nervous system depressants [including alcohol]).
- •3. Use of prescription or OTC antihistamines within 24 hours prior to taking study medication. (Note exceptions: loratadine [Claritin], desloratadine [Clarinex], cetirizine [Zyrtec ], levocetirizine [Xyzal], fexofendadine [Allegra], and azelastine [Intranasal, Astelin]).
- •4. Use of a bisphosphonate (e.g., pamidronate [Aredia], risedronate [Actonel], alendronate [Fosamax], or ibandronate [Boniva]) in the past 5-years.
- •5. Acute localized dental alveolar infection at the time of surgery that could confound the post-surgical evaluation.
- •6. Female subjects who are pregnant, lactating, of child-bearing potential or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine or intravaginal device [IUD or NuvaRing ], diaphragm, condom, abstinence, or surgical sterility including partner’s vasectomy), or who test positive on a urine-based pregnancy test.
- •7. Presence or history (within 2 years of enrollment) of gastrointestinal ulcer or gastrointestinal bleeding.
- •8. Presence or history (within 2 years of enrollment) of a bleeding disorder.
- •9. Presence or history of alcohol (3 or more alcoholic drinks per day on a regular basis) or substance abuse within 2 years of enrollment (note: one drink of alcohol is 1 oz. liquor, 6 oz. wine, or 12 oz. beer) or currently abusing other mood-altering drugs (e.g., cannabis). Patients who are taking St. John’s Wort, or any other nutritional supplement known to have psychotropic effects may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled.
- •10. Habituation to analgesic medications (i.e., routine use of oral analgesics 5 or more times per week).
- •11. Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID; or to APAP, hydrocodone, other opioids, or to their combinations.
- •12. Prior use of any type of analgesic or Non-Steroidal Anti Inflammatory Drug (NSAID) within five half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure.
- •13. Currently taking a monoamine oxidase inhibitor (MAOI), antipsychotic, or any other neuroleptic or has taken:
- •A MAOI within 2 months of screening (Note: subjects may not discontinue taking an MAOI solely for the purpose of qualifying for the study)
- •An antipsychotic or other neuroleptic within 14 days of surgery (Note: subjects may not discontinue taking these medications solely for the purpose of qualifying for the study)
- •14. Patients who are
研究者
相似试验
已完成
不适用
Ibuprofen and morphine for acute pain in sickle cell diseaseHaematological DisordersSickle-cell disordersSickle cell diseaseISRCTN97241637orth West London Hospitals NHS Trust (UK)320
进行中（未招募）
1 期
An Evaluation of the Effectiveness of Ibuprofen and Morphine for Acute Pain in Sickle Cell Disease - Ibuprofen and Morphine for Acute Sickle Cell PaiSickle Cell DiseaseEUCTR2008-006846-24-GBorth West London Hospitals NHS Trust320
已完成
3 期
Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental PainPainNCT01216163Pfizer218
进行中（未招募）
不适用
Study comparing ibuprofen and ibuprofen arginine in the control of spontaneous pain in patients with osteoarthritis and stabilized hypertension.EUCTR2011-003826-28-ITZAMBON S.p.A.
已完成
3 期
Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental PainPainNCT01098747Pfizer335